Σάββατο 2 Νοεμβρίου 2019


Syntaxin 6‐mediated exosome secretion regulates enzalutamide resistance in prostate cancer
Abstract Prostate cancer (PCa) deaths are typically the result of metastatic castration‐resistant PCa (mCRPC). Recently, enzalutamide (Enz), an oral androgen receptor inhibitor, was approved for treating patients with mCRPC. Invariably, all PCa patients eventually develop resistance against Enz. Therefore, novel strategies aimed at overcoming Enz resistance are needed to improve the survival of PCa patients. The role of exosomes in drug resistance has not been fully elucidated in PCa. Therefore,...
Molecular Carcinogenesis
Fri Nov 01, 2019 21:00
Clinical and Molecular Characterization of Primary Sclerosing Epithelioid Fibrosarcoma of Bone and Review of the Literature
ABSTRACT Sclerosing epithelioid fibrosarcoma (SEF) is a rare sarcoma subtype characterized by monomorphic epithelioid cells embedded in a densely sclerotic collagenous matrix. The overwhelming majority of tumors arise in soft tissues; however, rare cases have been documented to occur primarily in bone. The hallmarks of soft tissue SEF include MUC4 immunoreactivity and the presence of an EWSR1‐CREB3L1 fusion. Rare cases with alternative fusions have also been reported such as EWSR1‐CREB3L2 and FUS‐CREB3L2...
Genes, Chromosomes and Cancer
Fri Nov 01, 2019 16:33
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Abstract Drug repositioning is an emerging approach to developing novel cancer treatments. Vorinostat is a histone deacetylase inhibitor approved for cancer treatment, but it could attenuate its anticancer activity by activating the mammalian target of rapamycin (mTOR) pathway. The HMG‐CoA reductase inhibitor fluvastatin reportedly activates the mTOR inhibitor AMP‐activated protein kinase (AMPK), and we thought that it would potentiate vorinostat's anticancer activity in renal cancer cells. The...
Cancer Science
Fri Nov 01, 2019 21:49
Breast cancer incidence and mortality before and after implementation of the German mammography screening program
Effective population‐based mammography screening should impact breast cancer (BC) incidence, age and stage specific incidence and BC mortality. We aim to investigate such effects in a time period of ten years after implementation of the German mammography screening program. Data on 323,719 breast cancer patients from 2003 to 2014 for defined regions covering a population of 30 million inhabitants and official mortality data from 1998 to 2016 for almost the whole of Germany were used. We compared...
International Journal of Cancer
Fri Nov 01, 2019 17:55
Spatio‐temporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics
Metastasis is a multistep process, during which circulating tumor cells traffic through diverse anatomical locations. Stable inducible marking of tumor cells in a manner that is tightly spatially and temporally controlled would allow tracking the contribution of cells passing through specific locations to metastatic dissemination. For example, tumor cells enter the lymphatic system and can form metastases in regional lymph nodes, but the relative contribution of tumor cells that traffic through the...
International Journal of Cancer
Fri Nov 01, 2019 17:54
Risk of mature B‐cell neoplasms and precursor conditions after joint replacement: a report from the Haematological Malignancy Research Network
Associations between previous joint replacement and B‐cell lymphoid malignancies have been reported, but despite numerous reports, associations with the disease subtypes have received little attention. Using a UK‐based register of haematological malignancies and a matched general population‐based cohort, joint replacements from linked hospital inpatient records were examined. Cases diagnosed 2009‐2015 who were aged 50 years or more were included; 8,013 mature B‐cell neoplasms comprising myeloma (n=1,763),...
International Journal of Cancer
Fri Nov 01, 2019 17:48
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patient...
BMC Cancer - Latest Articles
Fri Nov 01, 2019 02:00
β-arrestin-2 up-regulates toll-like receptor 2 signaling and inhibits apoptosis in human endometrial cancer heterotransplants in nude mice
β-arrestin-2(Arr2) functions as an anti-apoptotic factor and affects cell proliferation, but its downstream molecular pathway in endometrial carcinoma (EC) is still unclear. This study aimed to investigate the...
BMC Cancer - Latest Articles
Fri Nov 01, 2019 02:00
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pa...
BMC Cancer - Latest Articles
Fri Nov 01, 2019 02:00
Clear cell sarcoma of the kidney in a 62-year-old patient presenting with generalized pruritus
Clear cell sarcoma of the kidney (CCSK) is the second most common renal tumor in children following Wilms’ tumor. CCSK is extremely rare in adults, with only 25 adult cases reported in the medical literature.
BMC Cancer - Latest Articles
Fri Nov 01, 2019 02:00
Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines
Women with ovarian cancer can present with a variety of symptoms and signs, and an increasing range of tests are available for their investigation. A number of international guidelines provide advice for the i...
BMC Cancer - Latest Articles
Fri Nov 01, 2019 02:00
The Role of miRNA in the Diagnosis, Prognosis, and Treatment of Osteosarcoma
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Cancer Biotherapy & Radiopharmaceuticals - Table of Contents
Fri Nov 01, 2019 09:00
Gilteritinib Improves Survival in Patients with Relapsed/Refractory FLT3+ AML
Treatment with gilteritinib improved survival and increased remission rates, compared with salvage chemotherapy, among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. (Source: CancerNetwork)
CancerNetwork
Fri Nov 01, 2019 05:00
Early Chemo Does Not Improve Survival in Endometrial Cancer
Endometrial cancer survival correlates with total number of chemotherapy cycles – but not whether they are started earlier than radiation, according to the results of a new study. (Source: CancerNetwork)
CancerNetwork
Fri Nov 01, 2019 05:00
MRTX849 Shows Clinical Activity in KRAS G12C-Mutant Cancers
A compound called MRTX849 is showing signs of being the first effective inhibitor of the KRAS G12C-mutant subtype of non-small cell lung and colorectal cancers. (Source: CancerNetwork)
CancerNetwork
Fri Nov 01, 2019 05:00
Yogurt, Fiber Consumption May Be Associated With Decreased Risk for Lung Cancer
The probiotics and prebiotics of yogurt and fiber consumption is associated with decreased risk of lung cancer. (Source: CancerNetwork)
CancerNetwork
Fri Nov 01, 2019 05:00
Psychiatric Disorders in Adolescent and Young Adult-Onset Cancer Survivors: A Systematic Review and Meta-Analysis
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Journal of Adolescent and Young Adult Oncology
Fri Nov 01, 2019 09:00
Emerging insights on the interaction between anticancer and immunosuppressant drugs and intestinal microbiota in pediatric patients
Abstract Diseases affecting the immune system such as inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA) and acute lymphoblastic leukemia (ALL) are pathological conditions affecting the pediatric population and are often associated with alterations in the intestinal microbiota, such as a decrease in bacterial diversity. Growing evidence suggests that gut microbiota can interfere with chemotherapeutic and immunosuppressant drugs, used in the treatment of these diseases, reducing...
Clinical and Translational Science
Fri Nov 01, 2019 16:21
Reduced risk of sinusoidal obstruction syndrome of the liver after Busulfan‐Cyclophosphamide conditioning prior to allogeneic hematopoietic stem cell transplantation
Abstract The aim of this study is to evaluate the incidence of sinusoidal obstruction syndrome (SOS) of the liver and the clinical outcome after hematopoietic stem cell transplantation (HSCT) based on several modifications in our protocols. We retrospectively investigated 372 patients undergoing myeloablative conditioning with oral busulfan and cyclophosphamide before allogeneic HSCT during 1990‐2015. Patients' supportive care was changed in order to reduce the regimen‐related toxicities. Norethisterone...
Clinical and Translational Science
Fri Nov 01, 2019 16:20
MiR-146a down-regulates inflammatory response by targeting TLR3 and TRAF6 in Coxsackievirus B infection [Article]
Coxsackievirus B (CVB) is the major cause of human myocarditis and dilated cardiomyopathy. Toll-like receptor 3 (TLR3) is an intracellular sensor to detect pathogen’s dsRNA. TLR3, along with TRAF6, triggers inflammatory response through NF-B signaling pathway. In the cells infected with CVB type 3 (CVB3), the abundance of miR-146a was significantly increased. The role of miR-146a in CVB infection is unclear. In this study, TLR3 and TRAF6 were identified as the targets of miR-146a. The elevated miR-146a...
RNA In Advance
Fri Nov 01, 2019 19:38
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Purpose: This randomized, multicenter, open-label, phase 1b/2 study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. Experimental Design: Second-line patients were randomized 2:2:1 to receive durvalumab plus tremelimumab (arm A), or durvalumab (arm B) or tremelimumab monotherapy (arm C), and third-line patients received durvalumab plus tremelimumab (arm D). A tumor-based interferon-gamma...
Clinical Cancer Research Online First Articles
Fri Nov 01, 2019 15:50
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia
Purpose: We investigated nilotinib exposure in pediatric patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant to, relapsed on, refractory to, or intolerant of previous treatment. Experimental Design: Fifteen patients (aged 1 to < 18 years) with CML resistant to or intolerant of imatinib and/or dasatinib (n = 11) or Ph+ ALL relapsed on or refractory to standard therapy (n = 4) enrolled in this phase 1 study. Nilotinib...
Clinical Cancer Research Online First Articles
Fri Nov 01, 2019 15:50
Modeling tumor evolutionary dynamics to predict clinical outcomes for patients with metastatic colorectal cancer: a retrospective analysis
Over 50% of colorectal cancer (CRC) patients develop resistance after a transient response to therapy. Understanding tumor resistance from an evolutionary perspective leads to better predictions of treatment outcomes. The objectives of this study were to develop a computational framework to analyze tumor longitudinal measurements and recapitulate the individual evolutionary dynamics in metastatic CRC (mCRC) patients. A stochastic modeling framework was developed to depict the whole spectrum of tumor...
Cancer Research Online First Articles
Fri Nov 01, 2019 15:36
Twist1-induced epithelial dissemination requires Prkd1 signaling
Dissemination is an essential early step in metastasis but its molecular basis remains incompletely understood. To define the essential targetable effectors of this process, we developed a 3D mammary epithelial culture model, in which dissemination is induced by overexpression of the transcription factor Twist1. Transcriptomic analysis and ChIP-PCR together demonstrated that protein kinase D1 (Prkd1) is a direct transcriptional target of Twist1 and is not expressed in the normal mammary epithelium....
Cancer Research Online First Articles
Fri Nov 01, 2019 15:36
Liposomal delivery of CRISPR/Cas9
Cancer Gene Therapy, Published online: 02 November 2019; doi:10.1038/s41417-019-0141-7Liposomal delivery of CRISPR/Cas9
Cancer Gene Therapy - AOP
02:00
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
NOTCH1 gene mutations in mantle cell lymphoma (MCL) have been described in about 5–10% of cases and are associated with significantly shorter survival rates. The present study aimed to investigate the biological ...
Journal of Experimental & Clinical Cancer Research - Latest Articles
Fri Nov 01, 2019 02:00
The spectrum of acute central nervous system symptoms during the treatment of childhood acute lymphoblastic leukaemia
Abstract Background Children with central nervous system (CNS) toxicity during therapy for acute lymphoblastic leukaemia (ALL) are at risk for treatment modifications, long‐term sequelae and even higher mortality. A better understanding of CNS symptoms and their complications improves the potential to prevent and treat them. Methods Patient files from 649 children treated with Nordic Society of Pediatric Hematology and Oncology ALL92 and ALL2000 protocols in Finland were reviewed retrospectively...
Pediatric Blood & Cancer
Fri Nov 01, 2019 11:43
NHS trust pays {pound}30m to boy branded “naughty” after behaviour is linked to birth inȷury
A 7 year old boy who has spent most of his life being branded naughty and disruptive has won a settlement of more than £30m (€35m; $39m) after it was discovered that he had sustained a brain injury...
British Medical Journal
Fri Nov 01, 2019 19:26
I’m a foster carer, please don’t call me mum
As a foster carer who has completed inpatient stays with children and attends multiple medical appointments, the issue of how carers are addressed is extremely important to me.1 Calling me mum not...
British Medical Journal
Fri Nov 01, 2019 18:11
Asking people how they want to be addressed is easy
I always cringe when I hear colleagues calling mothers “mum.”1 Fathers seem to be called “dad” less often in comparison.It seems to have a cultural element, being more commonly said by people from...
British Medical Journal
Fri Nov 01, 2019 17:11
Name badges for parents and carers
Nimmo explains why she doesn’t want to be addressed as mum.1Given that we are encouraged to introduce ourselves to patients, and to reinforce that with name badges, perhaps paediatric or other units...
British Medical Journal
Fri Nov 01, 2019 16:36
Switching patients to greener inhalers could be cost effective, study indicates
A study by UK researchers has highlighted the potential financial advantages of using respiratory inhalers that have less global warming impacts than those commonly in use.Their paper, published in...
British Medical Journal
Fri Nov 01, 2019 14:56
Juul shipped a million contaminated e-cigarette pods, claims lawsuit from former employee
The US electronic cigarette company Juul has been accused of shipping one million contaminated e-cigarette nicotine pods, in a lawsuit filed by a former employee.Siddharth Breja, who was the...
British Medical Journal
Fri Nov 01, 2019 13:51
Hypoxia‐induced HIF‐1α and ZEB1 are critical for the malignant transformation of ameloblastoma via TGF‐β‐dependent EMT
We aimed to clarify the mechanisms of malignant transformation of ameloblastoma or ameloblastic carcinoma carcinogenesis. We found that hypoxia‐induced HIF‐1a and ZEB1 are critical for the malignant transformation of ameloblastoma via TGF‐beta‐dependent EMT. Abstract Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification. AC develops pulmonary...
Cancer Medicine
Fri Nov 01, 2019 13:34
Low expression of long noncoding RNA CTC‐297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma
Our study demonstrated a novel long noncoding RNA CTC‐297N7.9, which expression was negatively correlated with the prognosis of hepatocellular carcinoma (HCC) patients, using bioinformatics analysis method and tissue specimen. CTC‐297N7.9 was proved to have potential to be a prognostic biomarker for HCC. Abstract Background Long noncoding RNAs (lncRNAs) are reported to play important roles in tumorigenesis of various malignant tumors. However, the clinical significance of aberrant lncRNA expression...
Cancer Medicine
Fri Nov 01, 2019 13:24
Role of alternative splicing signatures in the prognosis of glioblastoma
Applying the prognostic signatures constructed by independent alternative splicing events shows promise for predicting the survival of glioblastoma (GBM) patients. A splicing regulatory network might be the potential splicing mechanism in GBM. Abstract Background Increasing evidence has validated the crucial role of alternative splicing (AS) in tumors. However, comprehensive investigations on the entirety of AS and their clinical value in glioblastoma (GBM) are lacking. Methods The AS...
Cancer Medicine
Fri Nov 01, 2019 13:20
Photoimmunotherapy targeting biliary‐pancreatic cancer with humanized anti‐TROP2 antibody
The recently developed photoimmunotherapy (PIT) method targets and disrupts cancer cell membranes by combining monoclonal antibody (mAb)‐based targeting with a photosensitizer IR700. By using newly developed humanized anti‐TROP2 mAb conjugated to the IR700 (TROP2‐IR700), both pancreatic cancer and cholangiocarcinoma cells were successfully treated with near‐infrared light both in vitro and in vivo. Given that there is no molecular‐targeted therapy in the standard of care for pancreatic cancer and...
Cancer Medicine
Fri Nov 01, 2019 13:14
FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells
FEN1 is overexpressed in HeLa cell and the expression can be upregulated further by IR. FEN1 inhibitor enhances IR sensitivity of cervical cancer, and this enhancement effect was largely due to the impairment of DNA damage repair mechanism resulting from FEN1 inhibition, leading to apoptosis of cancer cells. Abstract Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing...
Cancer Medicine
Thu Oct 31, 2019 16:39

Increased risk for other cancers in individuals with Ewing sarcoma and their relatives
We used a unique resource linking genealogy from the mid 1800s to a statewide cancer registry from the mid 1960s to explore the association of cancers of other sites among Ewings sarcoma patients and their relatives. While this rare cancer was not observed to cluster in close relatives, multiple other cancer sites were observed among patients and their relatives and this data could inform the recommended cancer screening for this population. Abstract Background There are few reports of the association...
Cancer Medicine
Thu Oct 31, 2019 16:37
Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study
The objective of this manuscript was to describe the existing practice of small cell lung cancer (SCLC) care as a real‐world benchmark with which to assess the performance of the anticipated new immunotherapies. First‐line chemotherapy was largely platinum‐based, consistent with US guidelines while a variety of regimens were used for second‐ and third‐line chemotherapies, reflecting the lack of an accepted standard of care for these patients. Median survival from the start of each line of chemotherapy...
Cancer Medicine
Thu Oct 31, 2019 10:09
Incidence rates of cardiovascular outcomes in a community‐based population of cancer patients
In a cancer population not exposed to tyrosine kinase inhibitors or bevacizumab, cardiovascular outcomes are common, regardless of cancer type. Cardiovascular events occur more frequently in cancer patients with increasing numbers of cardiovascular risk factors. Abstract Background There are limited data on the incidence of cardiovascular disease among cancer patients in the pre‐tyrosine kinase inhibitor (TKI) era. Such data are important in order to contextualize the incidence of various cardiovascular...
Cancer Medicine
Wed Oct 30, 2019 20:43
COX7A1 suppresses the viability of human non‐small cell lung cancer cells via regulating autophagy
COX7A1 could inhibit cell proliferation and colony formation ability, as well as promote cancer cell apoptosis. COX7A1 overexpression blocked the autophagic flux via downregulation of PGC‐1α and upregulation of NOX2. Abstract COX7A1 is a subunit of cytochrome c oxidase, and plays an important role in the super‐assembly that integrates peripherally into multi‐unit heteromeric complexes in the mitochondrial respiratory chain. In recent years, some researchers have identified that COX7A1 is implicated...
Cancer Medicine
Wed Oct 30, 2019 11:36
Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial
Exposure of MCF‐7 cells to postoperative serum from patients receiving dexmedetomidine during surgery, but not control saline, had significantly higher proliferation, invasion, and migration than preoperative serum. The mean percentage changes from post to preoperative values in all these cellular malignant properties were also significantly larger in the Dex group compared with the control group. These findings suggest that the utilization of Dex during breast cancer surgery may modulate the patients'...
Cancer Medicine
Wed Oct 30, 2019 11:30
Single‐nucleotide polymorphisms in the coding region of a disintegrin and metalloproteinase with thrombospondin motifs 4 and hepatocellular carcinoma: A retrospective case‐control study
This relatively large‐size retrospective study was conducted to investigate the association between ADAMTS4 single‐nucleotide polymorphisms and the risk and prognosis of hepatocellular carcinoma (HCC). Both rs538321148 and rs1014509103 polymorphisms were identified to increase HCC risk and change tumor outcome, and they may be potential biomarkers for predicting HCC risk and prognosis. Abstract Previous studies have shown that single‐nucleotide polymorphisms (SNPs) of a disintegrin and metalloproteinase...
Cancer Medicine
Wed Oct 30, 2019 11:28
Worse characteristics can predict survival effectively in bilateral primary breast cancer: A competing risk nomogram using the SEER database
This study aimed to find out prognostic factors and put forward a new prognostic model in bilateral primary breast cancer from the Surveillance, Epidemiology, and End Results Database. We demonstrated that the new prediction was as effective as the model of bilateral tumors, however, more simply and convenient. Abstract Objective There is limited information from population‐based cancer registries regarding prognostic features of bilateral primary breast cancer (BPBC). Methods Female patients...
Cancer Medicine
Wed Oct 30, 2019 11:27
Helical tomotherapy for chemo‐refractory multiple liver metastases
Despite the remarkable advances of systemic chemotherapy for multiple liver metastases, the efficacy is still limited and cure of the multiple lesions is difficult. Helical tomotherapy for chemo‐refractory multiple liver metastases was suggested to be a feasible and potentially effective treatment with acceptable adverse events. Abstract Background Despite advances in chemotherapy, curing multiple liver metastases is quite rare. Even when response is obtained, regrowth of the tumors is almost...
Cancer Medicine
Tue Oct 29, 2019 17:49
Suspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case-control study.
Related ArticlesSuspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case-control study. Future Oncol. 2019 Oct 31;: Authors: McDonald L, Carroll R, Harish A, Tanna N, Mehmud F, Alikhan R, Ramagopalan SV Abstract Aim: To compare symptoms and blood test results prior to cancer diagnosis in individuals who developed lung cancer and those who did not. Patients & methods: Nested case-control study, lung...
Future Oncology.
Fri Nov 01, 2019 21:15
Cigarette smoking promotes cancer-related transformation of oral epithelial cells through activation of Wnt and MAPK pathway.
Related ArticlesCigarette smoking promotes cancer-related transformation of oral epithelial cells through activation of Wnt and MAPK pathway. Future Oncol. 2019 Oct 31;: Authors: Sarkar R, Das A, Paul RR, Barui A Abstract Aim: Study aims to investigate the effect of cigarette smoking on cancer-related transformation in oral epithelial cells of smokers through evaluating the alteration in Wnt/β-catenin and MAPK pathways. Materials & methods: Exfoliated...
Future Oncology.
Fri Nov 01, 2019 21:15
Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.
Related ArticlesBifidobacterium spp: the promising Trojan Horse in the era of precision oncology. Future Oncol. 2019 Oct 31;: Authors: Ngo N, Choucair K, Creeden JF, Qaqish H, Bhavsar K, Murphy C, Lian K, Albrethsen MT, Stanbery L, Phinney RC, Brunicardi FC, Dworkin L, Nemunaitis J Abstract Selective delivery of therapeutic agents into solid tumors has been a major challenge impeding the achievement of long-term disease remission and cure. The need to...
Future Oncology.
Fri Nov 01, 2019 21:15
Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial
Abstract Introduction Patients with NF2 who are deaf or have significant hearing loss face numerous and unique challenges which lead to poor quality of life, and thus may benefit from resiliency programs. Methods We performed secondary data analyses on a single blind, randomized controlled trial of an 8 week mind–body resiliency program (the Relaxation Response...
Latest Results for Journal of Neuro-Oncology
Fri Nov 01, 2019 02:00

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου